Thursday, November 19, 2020
Lineage Cell Therapeutics (LCTX)
Takeaways from Expert call on OpRegen
Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Lineage’s clinical programs are in markets with billion dollar opportunities and include three allogeneic (“off-the-shelf”) product candidates: (i) OpRegen®, a retinal pigment epithelium transplant therapy in Phase 1/2a development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase 1/2a development for the treatment of acute spinal cord injuries; and (iii) VAC, an allogeneic dendritic cell therapy platform for immuno-oncology and infectious disease, currently in clinical development for the treatment of non-small cell lung cancer. For more information, please visit www.lineagecell.com or follow the Company on Twitter @LineageCell.
Ahu Demir, Ph. D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
OpRegen data update. Lineage conducted a therapeutics expert call on November 17th following data presentation at the 2020 American Academy of Ophthalmology Annual Meeting (AAO) on November 15, 2020. The data update was from eight Cohort 4 patients with better visual acuity enrolled in Phase 1/2a (NCT02286089) clinical study assessing the lead product candidate, OpRegen for the treatment of dry age-related macular degeneration (AMD) with geographic atrophy (GA).
Interim showed encouraging signs. Among the eight patients from Cohort 4 (better visual acuity VA, <= 20/64 and >= 20/250), four patients were treated with PPV and the other four with Orbit device. Orbit device seems to improve eye-related adverse events in this small number of patient population. 3/5 patients, 4/4, and 4/4 patients had improvements in standard ETDRS letter reads at month 6, 9, and …
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.